Abstract
Epilepsy is a common neurological disorder that affects about one in a hundred people. It is one of the oldest documented diseases that has multiple causes and onset at any age. This article provides a brief overview of epilepsy and its treatment, together with a summary of the types of investigation that have been employed to improve greater understanding of this disease. A few landmark studies in epilepsy are identified.
References
- 1 Albert, P. S. (1991). A two-state Markov mixture model for a time series of epileptic seizure counts. Biometrics 47, 1371–1381.
- 2 Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., Lowenstein, D. H. (2001). A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. New England Journal of Medicine 345, 631–637.
- 3 Amery, W. & Dony, J. (1975). A clinical trial design avoiding undue placebo treatment, Journal of Clinical Pharmacology 15, 674–679.
- 4 Annegers, J. F., Hauser, W. A. & Elveback, L. R. (1979). Remission of seizures and relapse in patients with epilepsy, Epilepsia 20, 729–737.
- 5 Breslow, N. E. & Clayton, D. G. (1993). Approximate inference in generalized linear mixed models. Journal of the American Statistical Association 88, 9–25.
- 6 Browne, T. R. & Holmes, G. L. (2001). Epilepsy. New England Journal of Medicine 344, 1145–1151.
- 7 Coatsworth, J. J. (1971). Studies on the Clinical Efficacy of Marketed Antiepileptic Drugs. National Institute of Neurological Diseases and Stroke (NINDS) Monograph No 12, DHEW Publication No.(NIH) 73-51.
- 8 Goodridge, D. M. G. & Shorvon, S. D. (1983). Epileptic seizures in a population of 6000, British Medical Journal 287, 641–647.
- 9
Gram, L.
(1997).
Antiepileptic drug monotherapy designs in clinical trials.
Epilepsia
38,(Suppl. 5),
S14–S16.
10.1111/j.1528-1157.1997.tb04595.x Google Scholar
- 10 Hopkins, A., Davies, P. & Dobson, C. (1985). Mathematical models of patterns of seizures: their use in the evaluation of drugs, Archives of Neurology 42, 463–467.
- 11 Hutton, J. L. (2000). Number needed to treat: properties and problems. Journal of the Royal Statistical Society, Series A, 163, 403–419.
- 12 International League Against Epilepsy (1973). First Commission on Antiepileptic Drugs: Principles for clinical testing of antiepileptic drugs. Epilepsia 14, 451–458.
- 13 International League Against Epilepsy (1989). Guidelines for Clinical Evaluation of Antiepileptic Drugs, Epilepsia 30, 400–408.
- 14 International League Against Epilepsy (1992). International Glossary of Antiepileptic Drugs. Epilepsia 33,(Suppl. 2).
- 15 International League Against Epilepsy (1993). Guidelines for Epidemiologic Studies on Epilepsy, Epilepsia 34, 592–596.
- 16 International League Against Epilepsy (1993). Guidelines for Therapeutic Monitoring of Antiepileptic Drugs. Epilepsia 34, 585–587.
- 17 International League Against Epilepsy (1994). Guidelines for Antiepileptic Drug Trials in Children, Epilepsia 35, 94–100.
- 18 International League Against Epilepsy (1997). ILAE Commission Report. The epidemiology of the epilepsies: future directions. Epilepsia 38, 614–618.
- 19 International League Against Epilepsy (2002). ILAE Commission on the burden of epilepsy, Subcommission on the economic burden of epilepsy: final report 1998–2001. Epilepsia 43, 668–673.
- 20 International League Against Epilepsy (2002). ILAE Genetics Commission Conference Report: molecular analysis of complex genetic epilepsies. Epilepsia 43, 1262–1267.
- 21 Leber, P. D. (1989). Hazards of inference: the active control investigation, Epilepsia 30(Supplement 1), S57–S63.
- 22 Lesaffre, E. & Pledger, G. (1999). A note on the number needed to treat. Controlled Clinical Trials 20, 439–447.
- 23 Lowenstein, D. H., Alldredge, B. K., Allen, F., Neuhaus, J., Corry, M., Gottwald, M., O'Neil, N., Ulrich, S., Isaacs, S. M., Gelb, A. (2001). The prehospital treatment of status epilepticus (PHTSE) study: design and methodology. Controlled Clinical Trials 22, 290–309.
- 24 Marson, A. G., Kadir, Z. A. & Chadwick, D. W. (1996). New antiepileptic drugs: a systematic review of their efficacy and tolerability, British Medical Journal 313, 1169–1174.
- 25 Mattson, R. H., Cramer, J. A., Collins, J. F., Smith, P. B., Delgado-Escueta, A. V., Browne, T. R., Williamson, P. D., Treiman, D. M., McNamara, J., McCutchen, C. B. et al. (1985). Comparison of carbamazepine, phenobarital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures, New England Journal of Medicine 313, 145–151.
- 26 Medical Research Council Antiepileptic Drug Withdrawal Study Group (1991). Randomized study of antiepileptic drug withdrawal in patients in remission, Lancet 337, 1175–1180.
- 27 Medical Research Council Antiepileptic Drug Withdrawal Study Group (1993). Prognostic index for recurrence of seizures after remission of epilepsy. British Medical Journal 306, 1374–1378.
- 28 Milton, J. G., Gotman, J., Remillard, G. M., Andermann, F. (1987). Timing of seizure recurrence in adult epileptic patients: a statistical analysis. Epilepsia 28, 471–478.
- 29 Pledger, G. W. & Kramer, L. D. (1991). Clinical trials of investigational antiepileptic drugs: monotherapy designs, Epilepsia 32, 716–721.
- 30 Racine-Poon, A. & Dubois, J. P. (1989). Predicting the range of plasma carbamazepine concentrations in patients with epilepsy, Statistics in Medicine 8, 1327–1337.
- 31 Rettig, J. H. (1956). Chlorpromazine and mysoline in the control of convulsive epilepsy in mentally deficient patients. Journal of Nervous and Mental Disorders 124, 607–611.
- 32 Sabers, A. & Gram, L. (2000). Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 60, 23–33.
- 33 Sander, J. W. A. S. & Shorvon, S. D. (1987). Incidence and prevalence studies in epilepsy and their methodological problems: a review, Journal of Neurology, Neurosurgery and Psychiatry 50, 829–839.
- 34 Sander, J. W. A. S., Hart, Y. M., Johnson, A. L. & Shorvon, S. D. (1990). National General Practice Study of Epilepsy, Lancet 336, 1267–1274.
- 35 Schwade, E. D., Richards, R. K., Everett, G. M. (1956). Peganone, a new anticonvulsant drug. Diseases of the Nervous System 17, 155–158.
- 36 Shofer, J. B. & Temkin, N. R. (1986). Comparison of alternative outcome measures for antiepileptic drug trials, Archives of Neurology 43, 877–881.
- 37 Spilker, B. & Segreti, A. (1984). Validation of the phenomenon of regression of seizure frequency in epilepsy, Epilepsia 25, 443–449.
- 38 Thall, P. F. & Vail, S. C. (1990). Some covariance models for longitudinal count data with overdispersion, Biometrics 46, 657–671.
- 39 M. R. Trimble & W. E. Dodson, eds (1994). Epilepsy and Quality of Life. Raven Press, New York.
- 40 Wiebe, S., Blume, W. T., Girvin, J. P., Eliasziw, M., for the Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group (2001). A randomised, controlled trial of surgery for temporal-lobe epilepsy. New England Journal of Medicine 345, 311–318.
- 41 Williamson, P. R., Clough, H. E., Hutton, J. L., Marson, A. G., Chadwick, D. W. (2002). Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. Statistics in Medicine 21, 2613–2622.
- 42 Williamson, P. R., Tudur Smith, C., Hutton, J. L., Marson, A. G. (2002). Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 21, 3337–3351.
Citing Literature
